Stocks · News reference
aTyr Pharma Announces It Expects FDA Response Regarding Its Submitted Protocol For Phase 3 Trial Of Efzofitimod To Treat Pulmonary Sarcoidosis With Restrictive Lung Disease In Mid-September
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
aTyr Pharma CFO Jill Broadfoot To Step Down As Of September 30; To Be Succeeded By Brandon Yaras As Of October 1
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase
aTyr Pharma CFO Jill Broadfoot To Step Down Sept. 30, 2026